Adalimumab biosimilar - Boehringer Ingelheim

Drug Profile

Adalimumab biosimilar - Boehringer Ingelheim

Alternative Names: Adalimumab-adbm; BI-695501; Cyltezo

Latest Information Update: 20 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Ankylosing spondylitis; Crohn's disease; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
  • Preregistration Hidradenitis suppurativa; Panuveitis

Most Recent Events

  • 15 Sep 2017 The CHMP recommends approval of adalimumab biosimilar for Rheumatoid arthritis, Psoriatic arthritis, Crohn's disease, Ankylosing spondylitis, Ulcerative colitis, Plaque psoriasis, Hidradenitis suppurativa, Panuveitis and Juvenile idiopathic arthritis in European Union
  • 15 Sep 2017 The decision of the European Commission on the approval of adalimumab biosimilar is expected in the fourth quarter of 2017
  • 29 Aug 2017 AbbVie initiates litigation against Boehringer Ingelheim over adalimumab related patents in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top